Program
Diphenhydramine
Also written as “Ibuprofen and Diphenhydramine Citrate”, “Diphenydramine” and “Diphenhydramine Hydrochloride Injection”.
Its studies are mostly in Sleep Initiation and Maintenance Disorders · Nasal Obstruction · Multiple Sclerosis · Depressive Disorder, Major · Urticaria, led by 9 companies.
Drug pageDiphenhydramine: every studyMany companies study it; this page follows only the 13 they lead. All 67 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 40 open or running | phase 4since Mar 20, 2008 | Mar 20, 2008 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Jan 20, 2010 | Jan 20, 2010 | none ahead |
| Lumara Healthits history only | 10 open or running | phase 2since Dec 26, 2007 | Dec 26, 2007 | none ahead |
| Lunan Pharmaceutical Groupits history only | 11 open or running | phase 3since Feb 6, 2025 | Feb 6, 2025 | none ahead |
| Otsukaits history only | 10 open or running | phase 1since Nov 25, 2012 | Nov 25, 2012 | none ahead |
| Overseas Pharmaceuticalsits history only | 10 open or running | phase 1since Feb 6, 2023 | Feb 6, 2023 | none ahead |
| Pfizerits history only | 10 open or running | phase 1since May 5, 2010 | May 5, 2010 | none ahead |
| Procter and Gambleits history only | 10 open or running | phase 4since Oct 14, 2015 | Oct 14, 2015 | none ahead |
| TerSera Therapeuticsits history only | 10 open or running | phase 2since Dec 3, 2019 | Dec 3, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 26, 2007First study: phase 2 study in VulvodyniaNew to Lumara HealthLumara Health · NCT00590590 · 105 enrolled · United States, Canada
- Mar 20, 2008Johnson & Johnson’s first study: phase 1 study in Nasal ObstructionNew to Johnson & JohnsonJohnson & Johnson · NCT00662337 · 36 enrolled
- Mar 20, 2008Phase 4 study in Nasal ObstructionJohnson & Johnson · NCT00648973 · 1,021 enrolled · United States
- Sep 26, 2008Phase 1 study in Rhinitis, AllergicJohnson & Johnson · NCT00762749 · 36 enrolled · United States
- Jan 20, 2010Dr. Reddy's Laboratories’ first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01053338, NCT01053208
- May 5, 2010Pfizer’s first study: phase 1 study in HealthyNew to PfizerPfizer · NCT01119222 · 19 enrolled · Belgium
- Nov 25, 2012Otsuka’s first study: phase 1 study in HealthyNew to OtsukaOtsuka · NCT01737931 · 120 enrolled · Korea, Republic of
- May 29, 2015Phase 1 study in Depressive Disorder, MajorJohnson & Johnson · NCT02476058 · 48 enrolled · Belgium, Germany, Netherlands
- Oct 14, 2015Procter and Gamble’s first study: phase 4 study in Occasional SleeplessnessNew to Procter and GambleProcter and Gamble · NCT02578186 · 33 enrolled
- Dec 3, 2019TerSera Therapeutics’ first study: phase 2 study in Oncology Patients Receiving ChemotherapyNew to TerSera TherapeuticsTerSera Therapeutics · NCT04189588 · 34 enrolled · United States
- Feb 6, 2023Overseas Pharmaceuticals’ first study: phase 1 study in PainNew to Overseas PharmaceuticalsOverseas Pharmaceuticals · NCT05729555 · 16 enrolled · China
- Feb 6, 2025Lunan Pharmaceutical Group’s first study: phase 3 study in Acute UrticariaNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT06819774 · 284 planned · China
TargetBeta
“Histamine H1 receptor antagonist; Histamine H1 receptor antagonist”ChEMBL 37, by rule
Other programs on HRH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| desloratadinerule | Organon | phase 4 | 40 |
| fexofenadinerule | Sanofi | phase 4 | 38 |
| bilastinerule | faes-farma-s-a | phase 4 | 19 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06819774Acute Urticaria · China | 3 | Recruiting | Lunan Pharmaceutical Group | Aug 2025 | 284 |
| NCT05729555Pain · China | 1 | UNKNOWN | Overseas Pharmaceuticals | Oct 31, 2023 | 16 |
| NCT04189588Oncology Patients Receiving Chemotherapy · United States | 2 | Completed | TerSera Therapeutics | Nov 23, 2020 | 34 |
| NCT02578186Occasional Sleeplessness | 4 | Completed | Procter and Gamble | Dec 2014 | 33 |
| NCT02476058Depressive Disorder, Major · Belgium, Germany, Netherlands | 1 | Completed | Johnson & Johnson | Jan 4, 2016 | 48 |
| NCT01737931Healthy · Korea, Republic of | 1 | Completed | Otsuka | Oct 2012 | 120 |
| NCT01119222Healthy · Belgium | 1 | Completed | Pfizer | Oct 2008 | 19 |
| NCT01053338Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Apr 2008 | 40 |
| NCT01053208Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Apr 2008 | 40 |
| NCT00762749Rhinitis, Allergic · United States | 1 | Completed | Johnson & Johnson | Nov 2008 | 36 |
| NCT00662337Nasal Obstruction | 1 | Completed | Johnson & Johnson | Nov 2006 | 36 |
| NCT00648973Nasal Obstruction · United States | 4 | Completed | Johnson & Johnson | May 2007 | 1,021 |
| NCT00590590Vulvodynia · United States, Canada | 2 | Completed | Lumara Health | Jun 2009 | 105 |
How it is read
Names in the registry
- “Diphenhydramine”, 2 entries
- “Ibuprofen and Diphenhydramine Citrate”, 2 entries
- “Diphenydramine”, 1 entry
- “Diphenhydramine Hydrochloride Injection”, 1 entry
- “Diphenhydramine 50 mg/mL”, 1 entry
Conditions, from the studies’ own filings
- Sleep Initiation and Maintenance Disorders, 2 studies
- Nasal Obstruction, 2 studies
- Multiple Sclerosis, 1 study
- Depressive Disorder, Major, 1 study
- Urticaria, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.